On October 18, 2022 Guangzhou Zhiyi Biotech reported that it was approved to start US Phase I trial of its live biopharmaceutical product to treat chemotherapy-induced diarrhea (CID) (Press release, Guangzhou Zhiyi Biotech, OCT 18, 2022, View Source [SID1234622113]). SK10, an inactivated Bacteroides fragilis-based LBP, has shown efficacy in CID models, according to Zhiyi. It is the first LBP product approved for CID trials globally. Zhiyi says the US approval is a milestone for the company, starting trials of an LBP product in the US and China. Earlier this year, Zhiyi raised $15 million in its B++ funding, bringing the total of three B rounds to $45 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!